Multinationals mull over investing in production in Russia
This article was originally published in Scrip
Members of the Moscow-based Association of International Pharmaceutical Manufacturers (AIPM) are evaluating up to $1 billion in joint investment in local production, Jostein Davidsen, director general of Nycomed Russia-CIS, told the recent Adam Smith Conferences' 15th Annual International Russian Pharmaceutical Forum in St Petersburg. He said that AIPM has established a task force and drafted a position paper.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.